.
In principle, a possible cure for type I diabetes might be an implantable device capable of performing the function of the destroyed ␤-cells: detecting blood glucose levels and releasing appropriate amounts of insulin into the blood stream in response. The development of a closed-loop mechanical device capable of both sensing glucose and secreting insulin has been difficult [14] .
In lieu of such a mechanical cure, a biological cure must be twofold: preventing further immune attack and replacing the destroyed ␤-cells. Notably, given that both type I and type II diabetes are now understood to include reduced ␤-cell mass and function, ␤-cell replacement therapy may be a viable treatment option for both types of diabetes.
Structure and function of the adult pancreas
The adult pancreas functions as two independent organs: exocrine and endocrine pancreas. The exocrine pancreas comprises 95% of the total pancreatic mass. Embedded within the exocrine acinar cells are clusters of endocrine cells, called islets of Langerhans (Fig. 1) .
The exocrine pancreas functions to produce secretory products critical to proper digestion: digestive enzymes, including trypsin, lipase, amylase and carboxypeptidase, and bicarbonate.
The enzymes are synthesized and secreted from the exocrine acinar cells, and a network of pancreatic ducts drains these enzymes to the duodenum. Bicarbonate is secreted from the epithelial cells lining these pancreatic ducts. Acinar cells can be identified by digestive enzyme expression, while duct cells can be identified by their expression of cytokeratins and lectins such as those bound by Dolichos Biflorus Agglutinin. Within an endocrine islet (each typically comprised of 100-1000 endocrine cells), approximately 60% (human) to 80% (mouse) of the cells are ␤-cells [15], which secrete insulin into the bloodstream. The remaining cell types within the islets are ␣-cells (secrete glucagon), ␦-cells (secrete somatostatin) and PP-cells (secrete pancreatic polypeptide) (Fig. 1). Insulin functions to decrease blood glucose levels and its effects include increased glycogen synthesis in liver and muscle cells as well as increased fatty acid synthesis in fat cells. ␤-cells are also characterized by the expression of C-peptide, a byproduct of de novo insulin production, Glut2, a glucose transporter, and Pdx1, a transcription factor required for ␤-cell function. Conversely, glucagon functions to increase blood glucose levels and has complementary effects, including increased glycogenolysis and subsequent glucose release from liver and muscle cells as well as lipolysis and fatty acid release from fat cells. Somatostatin has a short half-life and its role is a predominantly paracrine effect to refine blood sugar regulation by the islet: when insulin levels are high and blood glucose low, somatostatin inhibits insulin release and, when insulin is low and blood glucose high, it inhibits the release of glucagon.
Additionally, somatostatin acts in the gut to inhibit gastrointestinal hormone secretion, pepsin secretion, motility, and blood flow. The function of pancreatic polypeptide remains unclear. New evidence suggests that a fifth endocrine cell type may exist in the islet: the ghrelin-secreting cell [16, 17] . Ghrelin is thought to inhibit glucose-stimulated insulin secretion by ␤-cells [18, 19] and may prove to be an important regulator of metabolism and obesity. [20] . The severe shortage of islets from cadaver [20] [27, 28] , or varying growth conditions [29] [30] [31] [29, 30] . Though ES cell-derived insulin-positive cells underwent normal glucose-mediated insulin release, they contained 50 times less insulin per cell than normal islet cells [30] . Though these ES cellderived '␤-cells' were insulin immunoreactive, no insulin1 mRNA or C-peptide was detected [32] 
Acini cells (light brown) surround duct cells (dark brown). Clusters of endocrine islets exist within the exocrine pancreas and contain four types of endocrine cells: ␤-cells (red), ␣-cells (green), ␦-cells (yellow) and PP-cells (blue). Endocrine cells secrete hormones into blood vessels (dark red

␤-cell maintenance and expansion
As recently as 20 years ago, the accepted dogma was that one was born with all the pancreatic ␤-cells one would ever have [35] . [36] [37] [38] , 5-bromo-2Ј-deoxyuridine (BrdU) incorporation [39, 40] , tritiated thymidine incorporation [41] or expression of the cell cycle marker Ki67 [42] (Fig. 3) (Fig. 4) .
Furthermore, the forced cell cycle arrest of ␤-cells severely restricts postnatal ␤-cell mass [45] [46] [47] [48] [49] [63] or islets [7] [8] [9] 64] .
Most [70] [71] [72] . Bone marrow transplantation, however, has been associated with normalization of glycaemia and increased islet mass in diabetic mice [66, 67] . Diabetes is, to a great extent, an autoimmune [60, 73] . Though [78] . In Tgf-␣ overexpressing transgenic mice, Pdx1 expression is detected in the metaplastic ductal epithelium [79] and 6% of the epithelial cells in these metaplastic ducts express low levels of insulin [80] .
Reported evidence for spleen stem cells giving rise to ␤-cells
It was also claimed that spleen stem cells have the ability to give rise to new ␤-cells, based on the observation that infusions of splenocytes and complete Freund's adjuvant, when combined with temporary islet transplantation, reversed diabetes in new-onset diabetic non-obese diabetic (NOD) mice
In [85, 86] .
Reported evidence for acini stem cells giving rise to ␤-cells
In addition to pancreatectomy, it has been reported that islet cell neogenesis is stimulated by partial duct ligation and regulated by growth factors such as gastrin and transforming growth factor (Tgf) [84]. Based on partial duct ligation experiments, an alternate model of pancreatic injury repair via transdifferentiation of acinar cells to islets has been suggested
Gastrin infusion following partial duct ligation results in a doubling of the ␤-cell mass as measured by morphometry [86] . This increase was not observed to be associated with increased ␤-cell proliferation, ␤-cell hypertrophy or reduced ␤-cell death, but instead with an increase in the percentage of single ␤-cells and small islet clusters. Colocalization of amylase and duct markers as well as amylase and insulin, was interpreted to suggest a direct transition from acinar to other pancreatic cell types [86, 87] .
It has also been reported that cultured exocrine cells can give rise to rare insulin-secreting cells that are immunoreactive for C-peptide, Pdx1 and Glut2 [85, 88, 89] [90, 91] or duct cells [91] [6, 9] or embryonic pancreatic progenitor [10] genes or by screening for colony forming ability [7, 8] [7] .
They purified a population of cells from whole adult pancreas that expresses the hepatocyte growth factor receptor c-Met but not haematopoietic or vascular markers [8]. These pancreatic cells formed clonal colonies at a frequency of ~0.03% in vitro and could differentiate into cells expressing markers consistent with pancreatic endocrine and exocrine fate, as well as liver, stomach and intestine. Similarly, another group reported that colony forming cells could be isolated from adult pancreatic islet or duct preparations at a frequency of ~0.02%, but did not characterize the cell surface marker or gene expression profiles of these colony forming cells. These single cell clones generated colonies of 2000-10,000 cells that expressed markers of neural, glial, pancreatic endocrine, exocrine and duct identities
Notably, nearly all ␤-cells in healthy adult mice and human beings are generated through the replication of existing ␤-cells [42, 43, 50, 53] . The papers described in this section [6] [7] [8] [9] [10] describe rare cell populations and provide no evidence towards the in vivo role of these putative stem cell populations in ␤-cell growth and maintenance. The known rate of ␤-cell replication is sufficient to account for all new ␤-cells generated in neonatal and adult mice [42, 43, 50, 53] . To date, there is no evidence that in healthy adult mice or human beings, any stem cell contributes to the ␤-cell population. [40] , the fundamental assumption of a constant rate of ␤-cell replication throughout adulthood is erroneous. Likely, ␤-cells are much older than previously hypothesized. [40, 48, 96, 97] 
␤-cell turnover
The lifespan of an individual ␤-cell cannot be directly assayed. Instead, ␤-cell half-life is estimated based on the rate of cell proliferation and death within the population. The absolute value of both rates remains contentious as they vary greatly with age. The ␤-cell half-life has not been definitively quantified. Based on ␤-cell mass measurements and an estimate of ␤-cell proliferation of 2% per day throughout adulthood, Finegood et al. calculated the ␤-cell lifespan to be 52 days [95]. This estimate is flawed in two respects: it is highly dependent on an accurate measurement of the ␤-cell replication rate and it assumes a constant rate of ␤-cell proliferation throughout adulthood. For example, if the replication rate approached a constant level of only 1% per day, the oldest ␤-cells would be 103 days old. Given that recent findings demonstrate that ␤-cell proliferation rates decline to less than 0.1% per day in 1-year-old mice
The absolute death rate of ␤-cells is unknown. TUNEL analysis of wild-type ␤-cells consistently fails to identify apoptotic cells
␤-cell mass is dynamic
Although it is not generally maintained by stem cells, the ␤-cell mass is dynamic and can respond to environmental cues such insulin and glucose physiology [36, 98, 99] . ␤-cell replication increases during neonatal growth [95] , pregnancy [100, 101] , and in cases of insulin resistance [102] . ␤-cells are capable of replication and are therefore viable targets for in vitro or in vivo expansion, though the mechanism regulating ␤-cell expansion remains unclear.
At the moment, it remains unclear how many independent pathways are capable of affecting ␤-cell replication, and what extrinsic signals, if any, regulate these pathways. It is unknown whether the rate of ␤-cell replication changes in direct response to glucose and/or insulin levels, or whether a circulating factor affects ␤-cell growth. It is possible that many means of regulating ␤-cell growth exist and that changes in ␤-cell replication in response to age, pregnancy and insulin resistance occur by unrelated processes. A better understanding of the extracellular cues and the intracellular mechanisms responsible for altering rates of ␤-cell replication will facilitate efforts to expand ␤-cells in vitro.
␤-cell replication changes with age
To compensate for increasing metabolic needs, ␤-cell number increases dramatically in the first year of life in rodents [43, 103] . The rate of ␤-cell replication changes significantly during the life of mice and rats: from ~20% per day in pups to ~10% per day at weaning, 2-5% per day in young adults and ~0.07% per day in aged 1-yearold mice [40, 50, 95] . The mechanism responsible for this decrease in ␤-cell replication with time is unknown. It is unclear whether this decrease in ␤-cell replication with age is an intrinsic property of ␤-cells or whether it occurs in response to decreasing levels of a circulating ␤-cell growth factor. The ability to restore neonatal ␤-cell growth rates to aged ␤-cells would be a substantial innovation.
␤-cell replication increases during pregnancy
During pregnancy in mice, rats and human beings, rates of ␤-cell replication increase up to 1.5-fold [50, 100, 101, 104, 105] [105] . Finally, changes in islet cell proliferation and insulin secretion during pregnancy have been correlated to serum lactogen levels [104, 107] . It is therefore likely that circulating factors, specifically lactogens, affect ␤-cell mass during pregnancy.
Over the first 10 days postpartum, this increased ␤-cell mass reverses as a result of reduced ␤-cell proliferation and increased apoptosis [100, 108] . These changes are also correlated to lactation; lactating rats have lower blood glucose, lower circulating insulin levels and less ␤-cell mass than non-lactating rats [108, 109] . The cause of the rapid loss of ␤-cell mass following parturition remains unclear. [36, 98, 99] 
␤-cell replication increases in cases of increased blood glucose and/or insulin resistance
␤-cells can respond to environmental factors such as glucose and insulin
, though it is often difficult to discern the individual effects of either glucose or insulin in vivo as the two cues generally occur in tandem. In rats, a 2-to 4-day infusion of glucose and/or insulin was claimed to result in a 50-75% increase in
␤-cell mass [36, 98] though in mice, a four-day glucose infusion was recently shown to induce a fivefold increase in ␤-cell replication but no significant increase in islet mass or number [99] . [99] .
Glucose infusion increases ␤-cell replication in a dose-dependent manner, and though hyperglycaemia and hyperinsulinaemia occur immediately after infusion begins, ␤-cell replication increases only after a delay of several days, possibly resulting from an increased abundance and nuclear localization of a key cell cycle protein, cyclin D2, involved in ␤-cell replication
It has previously been suggested that insulin or insulin growth factor (Igf) signalling may be responsible for regulating glucoseinduced ␤-cell proliferation [110, 111] 
. Insulin and Igf signalling is mediated via two intracellular insulin receptor substrates (Irs1 and Irs2); null mutations in either Irs1 or Irs2 result in peripheral insulin resistance but only Irs2
Ϫ/-mice are incapable enhancing ␤-cell replication to compensate for peripheral insulin resistance [112, 113] . [114, 115] or inhibition of Gsk3 [116, 117] [118] . It remains unclear whether the increase in ␤-cell mass that occurs in cases of insulin resistance is induced by hyperglycaemia, hyperinsulinaemia and/or a yet unidentified circulating factor [119] .
Irs2 is believed to stimulate ␤-cell proliferation by activating phosphoinositide-3-kinase (PI3K), which activates the serine/threonine kinase Akt, which in turn inactivates glycogen synthase kinase 3 (Gsk3) and activates cell cycle inhibitors. Overexpression of Akt
Many mouse models have been developed with which to study the consequences of insulin resistance. Insulin receptor (IR)-null mice exhibit acute insulin resistance and die within 72 hours of birth [118] . Irs2-null mice are diabetic but incapable of ␤-cell proliferation in response to insulin resistance [112] . Irs1-null mice are insulin resistant but also severely growth retarded [120, 121] [102] . Liver-specific insulin receptor knockout (LIRKO) mice exhibit dramatic insulin resistance, severe glucose intolerance, hyperinsulinaemia (fivefold elevated plasma insulin levels) and increased ␤-cell mass (sixfold) [122] . Finally, a ␤-cell specific knockout of the insulin receptor (␤IRKO), results in insulin resistance but not increased ␤-cell replication, suggesting that ␤-cell IR-signalling is required for ␤-cell hyperplasia in response to insulin resistance [111] . Leptin receptor (Lepr)-null mice develop obesity due to overeating, decreased energy expenditure and excessive fat storage [123, 124] . The ␤-cell mass of Lepr Ϫ/-mice initially expands to compensate for increased peripheral insulin resistance, though ␤-cell mass ultimately decreases, resulting in severe hyperglycaemia [125] . There is also evidence from autopsies of human pancreas tissue to suggest a similar compensatory growth of ␤-cell mass in human cases of obesity [126] .
␤-cell replication is regulated by cell cycle genes
There is overwhelming evidence that the cyclin-dependent kinase4 (cdk4)-cyclinD complex is responsible for ␤-cell replication during neonatal and adult growth. Cdk4-cyclinD complexes phosphorylate proteins (including pRB, p107 and p130) responsible for cell cycle progression [127] . Cdk4-null mice are viable though they display reduced body and organ size; many tissues are unaffected, but these mice are diabetic due to proliferative defects in ␤-cells and infertile due to defects in spermatogenesis [128] . An as yet unexplained observation is that embryonic and adult ␤-cell replication seem to be regulated independently. The forced cell cycle arrest of ␤-cells, either via the deletion of the cell cycle genes cyclinD2 [45] , cdk4 [47] , or the transcription factor FoxM1 [49] , or via the overexpression of the cell cycle inhibitor p27
Cdk4 activity requires D-type cyclins (D1, D2, D3
Kip1 [48] , severely restricts postnatal ␤-cell mass but not embryonic ␤-cell mass. Notably, Irs1 signalling seems to have a predominant role in embryonic, but not adult ␤-cell growth [112, 120, 121] , whereas Irs2 signalling is essential for ␤-cell compensatory growth in adults, but not embryonic ␤-cell development [110, 112] . This distinct regulation of embryonic and postnatal ␤-cell replication leads one to speculate whether the signals responsible for regulating embryonic ␤-cell proliferation can be co-opted to increase adult ␤-cell growth. ␤-cell mitogens stimulate progression through the G1 phase of the cell cycle, at least in part by stimulating activity of the cdk4-cyclinD complex. For example, prolactin and growth hormone are both known to stimulate STAT5 activation of cyclinD2 expression in mice [132, 133] . It remains to be seen whether the increased ␤-cell replication observed in pregnancy is also achieved through this mechanism, but evidence suggests that in pregnancy, prolactin not only increases STAT5 signalling, it also reduces the levels of the tumour suppressor gene menin, which is a known inhibitor of Cdk2 activity [134, 135] . Furthermore, evidence is now beginning to link increased cdk4-cyclinD activity to the increased ␤-cell replication observed in response to environmental cues such glucose infusion [99] and insulin resistance [48] [137] [138] [139] . Though the mechanism by which GLP-1R agonists increase ␤-cell replication is still relatively unclear, it now seems that the effects are mediated through Pdx1, Irs2 and Akt [138, [140] [141] [142] , while the mechanism of action of GIP receptor agonists is even less well understood but may occur via phosphatidylinositol 3-kinase (PI3K) [143] . Whether GLP-1 or GIP help to regulate ␤-cell replication in healthy mice remains a mystery, however, as the half life of these peptides in blood circulation is extremely short and estimated to be less than 90 seconds [144, 145] or 5 minutes [146, 147] , respectively.
Circumstantial evidence now suggests that the increase in ␤-cell replication during pregnancy and insulin resistance is likely due to a circulating factor. Several hormones known to be upregulated during pregnancy, including prolactin and placental lactogen [104, 106, 107] , have been associated with changes in ␤-cell proliferation in vitro. Additionally, the transplantation of wild-type islets into insulin-resistant mice leads to a marked increase in ␤-cell replication while transplantation of insulin-resistant islets into normal mice leads to reduced replication [119] [148] . The transcription factor hepatocyte nuclear factor 4␣ (Hnf4␣) regulates ␤-cell proliferation genes and Hnf4␣-null mice fail to expand ␤-cells in response to physiological demands [149] . Furthermore, haploinsufficiency of Pdx1 limits ␤-cell hyperplasia in insulin resistant mice [96] 
In vitro culture of ␤-cells
Attempts to expand ␤-cells in vitro have been difficult. Typically, purified islets divide slowly in culture, lose insulin expression and are gradually overtaken by insulin negative cells [152] [153] [154] [155] . Recent data from three groups, however, suggested cultured human islets can dedifferentiate and expand, via an epithelialmesenchymal transition, and then be directed to redifferentiate back toward a ␤-cell phenotype [9, 52, 156] . As cells expand, they express nestin and the mesenchymal marker vimentin, but not islet hormones [9, 156] 
